CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era

AIDS

Volumn 24, Issue 17, 2010, Pages 2697-2704

  Lodi, Sara ^a   Phillips, Andrew ^b   Touloumi, Giota ^c   Pantazis, Nikos ^c   Bucher, Heiner C ^d   Babiker, Abdel ^a   Chêne, Geneviève ^e   Vanhems, Philippe ^f,g   Porter, Kholoud ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g UNIVERSITÉ LYON 1   (France)

Author keywords

CD4 decline; HIV; natural history; repeat testing; seroconverters; seroprevalent

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ZIDOVUDINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE COURSE; FEMALE; FOLLOW UP; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MONOTHERAPY; PRIORITY JOURNAL; SEROCONVERSION; SEROPREVALENCE; SEX DIFFERENCE;

EID: 78349262304     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833ef6c4     Document Type: Article

References (35)

1. CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV infection. Lancet 2000; 355:1158-1159.
2. Lyles RH, Munoz A, Yamashita F, Bazmi H, Detels R, Rinaldo CR, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000; 181:872-880.
3. CASCADE Collaboration. Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1 infected in-dividuals with known dates of seroconversion. J Acquir Immun Defic Syndr 2003; 34:76-83.
4. (eART-linc) Collaboration. Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect 2008; 84(Suppl 1):i31-i36.
5. Leaity S, Sherr L, Wells H, Evans A, Miller R,Johnson M, Elford J. Repeat HIV testing: high-risk behaviour or risk reduction strategy? AIDS 2000; 14:547-552.
6. Elford J, Leaity S, Lampe F, Wells H, Evans A. Incidenceof HIV infectionamonggaymen ina London HIVtestingclinic,1997-1998. AIDS 2001; 15:650-653.
7. Wiley D, Visscher B, Grosser S, Hoover D, Day R, Gange S, et al. Evidence that anoreceptive intercourse with ejaculate expo-sure isassociatedwith rapidCD4cell loss. AIDS 2000; 14: 707-715.
8. Buchacz K, Patel P, Taylor M, Kerndt P, Byers R, Holmberg S, Klausner J. Syphilis increases HIVviral loadand decreasesCD4 cell counts in HIV-infected patients with new syphilis infec-tions. AIDS 2004; 18:2075-2079.
9. Sheth PM, Sunderji S, Shin LY, Rebbapragada A, Huibner S, Kimani J, et al. Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. J Infect Dis 2008; 197:1394-1401.
10. Gottlieb GS, Nickle DC, Jnesen MA, Wong KG, Grobler J, Li f, Liu SL. Dual HIV-1 infection associated with rapid disease progression. Lancet 2004; 363:619-622.
11. Lindback S, Brostrom C, Karlsson A, Gaines H. Does sympto-matic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 x 106/l, AIDS, and death from AIDS? BMJ 1994; 309:1535-1537.
12. Vanhems P, Lambert J, Cooper DA, Perrin L, Carr A, Hirschel B, et al. Severity and prognosis ofacute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis 1998; 26:323-329.
13. CASCADE Collaboration. Determinants of survival following HIV seroconversion after the introduction of HAART. Lancet 2003; 362:1267-1274.
14. CASCADE collaboration. Changes in the uptake of antiretro-viral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med 2000; 1:224-231.
15. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343:866-867.
16. Royston P, Sauerbrei W. The use of fractional polynomials to model continous risk variables in epidemiology. Int J Epidemiol 1999; 28:964-974.
17. Durban M, Harezlak J, Wand MP, Carroll RJ. Simple fitting of subject-specific curves for longitudinal data. Statist Med 2005; 24:1153-1167.
18. CASCADE Collaboration. The relationships between the HIV test interval, demographic factors and HIV disease progression. Epidem Infect 2001; 127:91-100.
19. Tyrer F, Walker J, Gillett J, Porter K. The relationship between HIVseroconversion illness, HIVtestinterval andtimetoAIDS in aseroconvertercohort. Epidem Infect2003; 131:1117-1123.
20. Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, et al. Safety and efficacy of lamivudine-zidovu-dine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine mono-therapy. JAMA 1996; 276:118-125.
21. Touloumi G, Pocock SJ, Babiker A, Darbyshire J. Estimationand comparison of rates of change in longitudinal studies with informative drop-outs. Stat Med 1999; 18:1215-1233.
22. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 2000; 19:1141-1164.
23. Vanhems P, Lambert J, Guerra M, Hirschel B, Allard R. Associa-tion between the rate ofCD4+ T cell decrease and the year of human immunodeficiency virus (HIV) type 1 seroconversion among persons enrolled in the Swiss HIV Cohort Study. J Infect Dis 1999; 142:636-642.
24. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. J Infect Dis 2000; 181:872-880.
25. Urassa W, Bakaru M, Sandstrom E, Swai A, Pallangyo K, Mbena E, et al. Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1 infected adults in Dar es Salaam, Tanzania. AIDS 2004; 18:433-438.
26. Drylewicz J, Matheron S, Lazaro, Damond F, Bonnet F, Simon F, et al. Comparison of viro-immunological marker changes be-tween HIV-1 and HIV-2 infected patients in France. AIDS 2008; 22:457-468.
27. Rodriguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M, et al. Predictive valueof plasma HIV RNA levelson rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006; 296:1498-1506.
28. Duvignac J, Anglaret X, Kpozehouen A, Inwoley A, Seyler C, Toure S, et al. CD4+ T-lymphocytes natural decrease in HAART-näive HIV-infected adults in Abidjan. HIV Clin Trials 2008; 9:26-35.
29. Wolbers M, Bucher H, Rickenbach M, Cavassini M, Weber R, Schmid P, et al. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIVMed2008; 9:397-405.
30. Borghi V, Girardi E, Bellelli S, Angeletti C, Mussini C, Porter K, Esposito R. Late presenters in an HIV surveillance system in Italy during the period 1992-2006. J Acquir Immune Defic Syndr 2008; 49:282-286.
31. UKCHIC. Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS 2010; 24: 723-727.
32. Dorrucci M, Rezza G, Porter K, Phillips A. Temporal trends in postseroconversion CD4 cell count and HIV load: the Con-certed Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. J Infect Dis 2007; 195:525-534.
33. th Conference on Retroviruses and Op-portunistic Infections. February 16-19, 2010. San Francisco, CA, US. Abstact 980. Available at http://www.retroconferen-ce.org/2010/PDFs/980.pdf. [Accessed 12 March 2010]
34. Schcker T, Hugher J, Shea T, Coomb R, Corey L. Biological and virological characteristics of primary infection. Ann Inten Med 1998; 128:613-620.
35. Kanki PJ, Hamel DJ, SankaléJL, Hsieh C, Thior I, Barin F, et al. Human immunodeficiency virus type 1 subtypes differ in dis-ease progression. J Infect Dis 1999; 179:68-73.